Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits.

BACKGROUND Prospective epidemiological studies support the hypothesis that high levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I limit atherosclerosis development. However, more data from studies with animal models of atherosclerosis that resemble the human disease are required to demonstrate the effect of apo A-I in the inhibition of atherogenesis. The rabbit is a good animal model for human atherosclerosis. METHODS AND RESULTS Human apo A-I-transgenic rabbits have been produced, and we have evaluated the effect of apo A-I on the development of atherosclerosis in transgenic rabbits fed a cholesterol-rich diet for 14 weeks. Plasma cholesterol levels of atherogenic apo B-containing lipoproteins were similar for transgenic and control rabbits (> 1000 mg/dL), while plasma levels of HDL cholesterol in the transgenic group were always about twice that of the control group (68 +/- 11 versus 37 +/- 3 mg/dL at 14 weeks; P < .001). At the end of the experiment, the amount of aortic surface area covered by lesions as well as the amount of lipid accumulation in the aorta were significantly less in transgenic rabbits compared with the control group (15 +/- 12% versus 30 +/- 8%, P < .0027 for the surface area of the thoracic aorta; 116 +/- 31 versus 247 +/- 39 mumol/g aorta, P < .0068 for cholesterol content in total aorta). CONCLUSIONS Overexpression of human apo A-I in rabbits inhibits the development of atherosclerosis in this animal model that resembles, in many respects, human atherosclerosis.

[1]  Y. Matsuzawa,et al.  Apo A-I and apo A-II inhibit hepatic triglyceride lipase from human postheparin plasma. , 1981, Biochemical and biophysical research communications.

[2]  D. Gordon,et al.  High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. , 1986, Circulation.

[3]  P. Denéfle,et al.  Transgenic rabbits expressing human apolipoprotein A-I in the liver. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[4]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[5]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[6]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Böttcher Cj,et al.  Chemical changes in the arterial wall associated with atherosclerosis. , 1962 .

[8]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[9]  M. J. Chapman.  [3] Comparative analysis of mammalian plasma lipoproteins , 1986 .

[10]  J. Avigan,et al.  Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. , 1978, Journal of lipid research.

[11]  C. Hunt,et al.  Hyperlipoproteinaemia and atherosclerosis in rabbits fed low-level cholesterol and lecithin. , 1985, British journal of experimental pathology.

[12]  W. Insull,et al.  Cholesterol, triglyceride, and phospholipid content of intima, media, and atherosclerotic fatty streak in human thoracic aorta. , 1966, The Journal of clinical investigation.

[13]  A. Gown,et al.  Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. , 1986, Arteriosclerosis.

[14]  P. Giral,et al.  A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  E. Rubin,et al.  Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. , 1994, Journal of lipid research.

[16]  P. Barter,et al.  The rabbit as an animal model of hepatic lipase deficiency. , 1989, Biochimica et biophysica acta.

[17]  Chun Yuan,et al.  Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo , 1995, Nature Medicine.

[18]  N. Miller.  Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. , 1987, American heart journal.

[19]  C. W. Adams,et al.  Lipoprotein levels and tissue lipids in fatty-fibrous atherosclerosis induced in rabbits by two years' cholesterol feeding at a low level. , 1982, Atherosclerosis.

[20]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[21]  W. J. Johnson,et al.  Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. , 1992, Journal of lipid research.

[22]  R. Lawn,et al.  Cloning and mRNA tissue distribution of rabbit cholesteryl ester transfer protein. , 1988, Journal of lipid research.

[23]  P. Barter,et al.  Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma. , 1990, Atherosclerosis.

[24]  S. Skarlatos,et al.  Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II. , 1995, Biochimica et biophysica acta.

[25]  H. Kruth,et al.  Development of unesterified cholesterol-rich lipid particles in atherosclerotic lesions of WHHL and cholesterol-fed NZW rabbits. , 1994, Journal of lipid research.

[26]  T. Bocan,et al.  Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  N. Simionescu,et al.  Development of intracellular lipid deposits in the lipid-laden cells of atherosclerotic lesions. A cytochemical and ultrastructural study. , 1987, Atherosclerosis.

[28]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[29]  C. Fielding,et al.  Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. , 1988, Biochemistry.

[30]  E. Rubin,et al.  Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. , 1994, Journal of Clinical Investigation.

[31]  J. Fruchart,et al.  Electroimmuno- and immunonephelometric assays of apolipoprotein A-I by using a mixture of monoclonal antibodies. , 1988, Clinical chemistry.

[32]  G. Shipley,et al.  Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. , 1976, The Journal of clinical investigation.

[33]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[34]  L. B. Roger,et al.  Effect of apolipoproteins on the hepatic lipase-catalyzed hydrolysis of human plasma high density lipoprotein2-triacylglycerols , 1982 .

[35]  W. Mack,et al.  Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.